Gynecologists' attitudes regarding human papilloma virus vaccination

A survey of Fellows of the American College of Obstetricians and Gynecologists

Janice C. Raley, Kristen A. Followwill, Gregory Zimet, Kevin A. Ault

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Background: Human papilloma virus (HPV) is the causative agent of cervical neoplasia and genital warts. A vaccine has recently been developed that may prevent infection with HPV. Vaccination for HPV may become a routine part of office gynecology. We surveyed members of the American College of Obstetricians and Gynecologists (ACOG) to determine their attitudes to HPV vaccination. Methods: A survey was sent to Fellows of ACOG to evaluate gynecologists' attitudes. Vaccine acceptability was analyzed using 13 scenarios with the following dimensions and respective attributes: age of patient (3, 17 and 22 years); efficacy of vaccine (50% or 80%); ACOG recommendation (yes or no); and disease targeted (cervical cancer, warts or both). Each scenario was rated by means of an 11-point response format (0 to 100). Responses were evaluated using conjoint analysis. Results: Of 1200surveys that were sent out, 181 were returned and included in our analysis. ACOG recommendation was considered the most important variable in vaccine distribution (importance score = 32.2), followed by efficacy (24.5), age (22.4) and, lastly, disease targeted (20.9). Of these variables, higher efficacy was favored; preference was given to age 17 years, with a strong disinclination to vaccinate at age 13 years; and protection against cervical cancer, or genital warts, or both, was significantly favored over a vaccine against genital warts alone. Demographic characteristics of the gynecologists (i.e., age of physician, gender, practice setting and community size) did not play an important role in the decision to recommend vaccination. Conclusion: Professional society recommendation is important for acceptability of a potential HPV vaccine. Gynecologists are willing to include this vaccine in their office practice.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalInfectious Diseases in Obstetrics and Gynecology
Volume12
Issue number3-4
DOIs
StatePublished - Sep 2004

Fingerprint

Papillomaviridae
Vaccination
Vaccines
Condylomata Acuminata
Uterine Cervical Neoplasms
Papillomavirus Vaccines
Warts
Gynecology
Surveys and Questionnaires
Demography
Physicians

Keywords

  • Adolescence
  • Cervical neoplasia
  • Human papilloma virus
  • Sexually transmitted diseases
  • Vaccine

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Dermatology

Cite this

Gynecologists' attitudes regarding human papilloma virus vaccination : A survey of Fellows of the American College of Obstetricians and Gynecologists. / Raley, Janice C.; Followwill, Kristen A.; Zimet, Gregory; Ault, Kevin A.

In: Infectious Diseases in Obstetrics and Gynecology, Vol. 12, No. 3-4, 09.2004, p. 127-133.

Research output: Contribution to journalArticle

@article{ce517fbb86934d88b4676bfea869f22d,
title = "Gynecologists' attitudes regarding human papilloma virus vaccination: A survey of Fellows of the American College of Obstetricians and Gynecologists",
abstract = "Background: Human papilloma virus (HPV) is the causative agent of cervical neoplasia and genital warts. A vaccine has recently been developed that may prevent infection with HPV. Vaccination for HPV may become a routine part of office gynecology. We surveyed members of the American College of Obstetricians and Gynecologists (ACOG) to determine their attitudes to HPV vaccination. Methods: A survey was sent to Fellows of ACOG to evaluate gynecologists' attitudes. Vaccine acceptability was analyzed using 13 scenarios with the following dimensions and respective attributes: age of patient (3, 17 and 22 years); efficacy of vaccine (50{\%} or 80{\%}); ACOG recommendation (yes or no); and disease targeted (cervical cancer, warts or both). Each scenario was rated by means of an 11-point response format (0 to 100). Responses were evaluated using conjoint analysis. Results: Of 1200surveys that were sent out, 181 were returned and included in our analysis. ACOG recommendation was considered the most important variable in vaccine distribution (importance score = 32.2), followed by efficacy (24.5), age (22.4) and, lastly, disease targeted (20.9). Of these variables, higher efficacy was favored; preference was given to age 17 years, with a strong disinclination to vaccinate at age 13 years; and protection against cervical cancer, or genital warts, or both, was significantly favored over a vaccine against genital warts alone. Demographic characteristics of the gynecologists (i.e., age of physician, gender, practice setting and community size) did not play an important role in the decision to recommend vaccination. Conclusion: Professional society recommendation is important for acceptability of a potential HPV vaccine. Gynecologists are willing to include this vaccine in their office practice.",
keywords = "Adolescence, Cervical neoplasia, Human papilloma virus, Sexually transmitted diseases, Vaccine",
author = "Raley, {Janice C.} and Followwill, {Kristen A.} and Gregory Zimet and Ault, {Kevin A.}",
year = "2004",
month = "9",
doi = "10.1080/10647440400020661",
language = "English",
volume = "12",
pages = "127--133",
journal = "Infectious Diseases in Obstetrics and Gynecology",
issn = "1064-7449",
publisher = "Hindawi Publishing Corporation",
number = "3-4",

}

TY - JOUR

T1 - Gynecologists' attitudes regarding human papilloma virus vaccination

T2 - A survey of Fellows of the American College of Obstetricians and Gynecologists

AU - Raley, Janice C.

AU - Followwill, Kristen A.

AU - Zimet, Gregory

AU - Ault, Kevin A.

PY - 2004/9

Y1 - 2004/9

N2 - Background: Human papilloma virus (HPV) is the causative agent of cervical neoplasia and genital warts. A vaccine has recently been developed that may prevent infection with HPV. Vaccination for HPV may become a routine part of office gynecology. We surveyed members of the American College of Obstetricians and Gynecologists (ACOG) to determine their attitudes to HPV vaccination. Methods: A survey was sent to Fellows of ACOG to evaluate gynecologists' attitudes. Vaccine acceptability was analyzed using 13 scenarios with the following dimensions and respective attributes: age of patient (3, 17 and 22 years); efficacy of vaccine (50% or 80%); ACOG recommendation (yes or no); and disease targeted (cervical cancer, warts or both). Each scenario was rated by means of an 11-point response format (0 to 100). Responses were evaluated using conjoint analysis. Results: Of 1200surveys that were sent out, 181 were returned and included in our analysis. ACOG recommendation was considered the most important variable in vaccine distribution (importance score = 32.2), followed by efficacy (24.5), age (22.4) and, lastly, disease targeted (20.9). Of these variables, higher efficacy was favored; preference was given to age 17 years, with a strong disinclination to vaccinate at age 13 years; and protection against cervical cancer, or genital warts, or both, was significantly favored over a vaccine against genital warts alone. Demographic characteristics of the gynecologists (i.e., age of physician, gender, practice setting and community size) did not play an important role in the decision to recommend vaccination. Conclusion: Professional society recommendation is important for acceptability of a potential HPV vaccine. Gynecologists are willing to include this vaccine in their office practice.

AB - Background: Human papilloma virus (HPV) is the causative agent of cervical neoplasia and genital warts. A vaccine has recently been developed that may prevent infection with HPV. Vaccination for HPV may become a routine part of office gynecology. We surveyed members of the American College of Obstetricians and Gynecologists (ACOG) to determine their attitudes to HPV vaccination. Methods: A survey was sent to Fellows of ACOG to evaluate gynecologists' attitudes. Vaccine acceptability was analyzed using 13 scenarios with the following dimensions and respective attributes: age of patient (3, 17 and 22 years); efficacy of vaccine (50% or 80%); ACOG recommendation (yes or no); and disease targeted (cervical cancer, warts or both). Each scenario was rated by means of an 11-point response format (0 to 100). Responses were evaluated using conjoint analysis. Results: Of 1200surveys that were sent out, 181 were returned and included in our analysis. ACOG recommendation was considered the most important variable in vaccine distribution (importance score = 32.2), followed by efficacy (24.5), age (22.4) and, lastly, disease targeted (20.9). Of these variables, higher efficacy was favored; preference was given to age 17 years, with a strong disinclination to vaccinate at age 13 years; and protection against cervical cancer, or genital warts, or both, was significantly favored over a vaccine against genital warts alone. Demographic characteristics of the gynecologists (i.e., age of physician, gender, practice setting and community size) did not play an important role in the decision to recommend vaccination. Conclusion: Professional society recommendation is important for acceptability of a potential HPV vaccine. Gynecologists are willing to include this vaccine in their office practice.

KW - Adolescence

KW - Cervical neoplasia

KW - Human papilloma virus

KW - Sexually transmitted diseases

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=11844279099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844279099&partnerID=8YFLogxK

U2 - 10.1080/10647440400020661

DO - 10.1080/10647440400020661

M3 - Article

VL - 12

SP - 127

EP - 133

JO - Infectious Diseases in Obstetrics and Gynecology

JF - Infectious Diseases in Obstetrics and Gynecology

SN - 1064-7449

IS - 3-4

ER -